{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Compliance with the ELLIPTA inhaler will be determined by reviewing the dose counter', 'on the ELLIPTA. Compliance with the study DISKUS will be determined by reviewing', 'the dose counter on the DISKUS. Subjects should be >80% to <120% compliant on', 'taking study medication between each pair of on-treatment visits. Subjects who fall', 'outside this range should be re-educated on treatment compliance by their site. This re-', \"education should be documented in the subject's source document. If medication\", 'compliance repeatedly falls outside of acceptable ranges, the study sponsor/site monitor', 'must be contacted to discuss subject eligibility for continued participation in the study.', '6.9.', 'Treatment of Study Treatment Overdose', 'An overdose is defined as a dose greater than the total doses described in Section 6.1 and', 'Section 6.8 which results in clinical signs and symptoms. These should be recorded by', 'the investigator on the AE/SAE pages. In the event of an overdose of study medication,', 'the investigator should use clinical judgment in treating the overdose and contact the', 'study Medical Monitor.', 'GSK is not recommending specific treatment guidelines for overdose and toxicity', 'management. The investigator is advised to refer to the relevant document(s) for detailed', 'information regarding warnings, precautions, contraindications, adverse events, and other', 'significant data pertaining to the study drug being used in this study. Such documents', 'may include, but may not be limited to, the approved product label for salmeterol', 'albuterol, UMEC and UMEC/VI or equivalent document provided by GSK.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the subject.', '6.10.', 'Treatment after the End of the Study', 'Subjects will not receive any additional treatment from GSK after completion of the', 'study, since the study treatments are commercially available.', 'The investigator is responsible for ensuring that consideration has been given to the post-', \"study care of the subject's medical condition, post-study treatment.\", '6.11.', 'Concomitant Medications and Non-Drug Therapies', 'All COPD medications used within 30 days prior to Pre-Screening (Visit 0) and onwards', 'should be recorded in the eCRF including any changes in medications. Beginning at', 'Visit 1 and throughout the rest of the study, all medications should be recorded in the', 'eCRF including any changes. Study provided albuterol/salbutamol and double-blinded', 'study drug should not be recorded in the eCRF. The minimum requirement includes but', 'is not limited to drug name, dose, route and the dates of administration. Medications', 'initiated after completion of Visit 5 or the Early Withdrawal Visit will not be recorded in', 'the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that', 'occurs between Visit 5 (or the Early Withdrawal Visit) and the follow-up contact at Visit', '6.', '41']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', '6.11.1.', 'Permitted Medications and Non-Drug Therapies', 'The following relevant medications are permitted during this study:', 'Study-provided albuterol/salbutamol for use as relief medication throughout the', 'run-in and treatment periods', 'Mucolytics such as acetylcysteine', 'Medications for rhinitis (e.g. intranasal corticosteroids, antihistamines, cromolyn,', 'nedocromil, nasal decongestants)', 'Influenza vaccine', 'pneumococcal vaccine', 'Antibiotics for short term treatment (<14 days) of acute infections including', 'COPD exacerbations', 'Systemic corticosteroids for short term (<14 consecutive days) treatment of', 'COPD exacerbations', 'As-needed supplemental oxygen use provided it is <3L/min flow at rest at', 'screening. Patients may adjust oxygen levels as needed during the study.', 'Pulmonary rehabilitation program in maintenance phase', 'Smoking cessation treatment, including a stable regimen of nicotine replacement', 'Use of positive airway pressure/non-invasive ventilation for sleep apnea/sleep', 'disordered breathing (e.g. CPAP, BiPAP)', 'Localized corticosteroid injections (e.g., intra-articular and epidural)', 'Oral muscarinic antagonists for the treatment of overactive bladder are permitted', 'but should be used with caution as they may exacerbate medical conditions that', 'are contraindicated for anticholinergics (e.g., narrow angle glaucoma and bladder', 'outflow obstruction)', 'Immunotherapy injections', 'Topical or ophthalmic corticosteroids', 'Over-the counter (OTC) cough suppressants', 'Tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs). Administer', 'with caution as they may potentiate the effect of beta-agonists on the vascular', 'system', 'Diuretics. Caution is advised in the co-administration of beta agonists with non-', 'potassium sparing diuretics', 'Allergy vaccination', 'All medications for other disorders as long as the dose remains constant whenever', 'possible and their use would not be expected to affect lung function', '42']\n\n###\n\n", "completion": "END"}